All In Biotech

Drug Trial Radar · NCT03651947

Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Oct 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Aug 20, 2018

Primary completion

Nov 17, 2018

Study completion May 22, 2019

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of QL1206 and Xgeva® in healthy adults.

Conditions

  • Healthy People

Interventions

  • QL1206Drug

    subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.

  • Xgeva®Drug

    subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve (AUC0-t )Time frame: 134 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.